Trends in antifungal susceptibility of Candida species – one year observation

• Autorzy: Golas M. , Netsvyetayeva I. , Sikora M. , Piskorska K. , Sulik-Tyszka B. , Swoboda-Kopec E.
• Języki publikacji: EN

Abstrakty

EN

In the past years opportunistic fungal infections have seriously increased, mainly in immunocompromised patients. The aim of the study was to determine the prevalence of yeast-like fungi in invasive candidiasis and to estimate its susceptibility to chosen antifungal agents. One hundred and sixty strains of yeast-like fungi were cultured from various clinical material: samples from lower respiratory tract, blood, the peritoneal cavity and others. The susceptibility tests were established according to the quantitative E-test method. The Candida genus represented the main etiological factor of invasive candidiasis. The predominant species were: C. glabrata (71/160), C. albicans (34/160), C. krusei (17/160), C. tropicalis (14/160). All tested strains were the most resistant to itraconazole. Candida glabrata presented the 100% susceptibility to amphotericin B and caspofungin and was the least susceptible to itraconazole, posaconazole and voriconazole. Candida albicans was the most susceptible species to all antymicotics.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2014
• Tom: 63
• Numer: 2
• Opis fizyczny: p.217-222,fig.,ref.

Twórcy

autor

Golas M.

• Department of Medical Microbiology, Warsaw Medical University, Chalubinskiego Str.5, 02-004 Warsaw, Poland

autor

Netsvyetayeva I.

• Department of Medical Microbiology, Warsaw Medical University, Chalubinskiego Str.5, 02-004 Warsaw, Poland

autor

Sikora M.

• Department of Dental Microbiology, Warsaw Medical University, Warsaw, Poland

autor

Piskorska K.

• Department of Medical Microbiology, Warsaw Medical University, Chalubinskiego Str.5, 02-004 Warsaw, Poland

autor

Sulik-Tyszka B.

• Department of Microbiology, Central Clinical Hospital, Warsaw, Poland

autor

Swoboda-Kopec E.

• Department of Dental Microbiology, Warsaw Medical University, Warsaw, Poland
• Department of Microbiology, Central Clinical Hospital, Warsaw, Poland

Bibliografia

• Arendrup M.C., B. Bruun, J.J. Christensen, K. Fuursted, H.K. Johansen, P. Kjaeldgaard, J.D. Knudsen, L. Kristensen, J. Møller, L. Nielsen and others. 2011. National surveillance of fungemia in Denmark 2004 to 2009. J. Clin. Microbiol. 49: 325–334.
• Arendrup M.C., S. Sulim, A. Holm, L. Nielsen, S.D. Nielsen, J.D. Knudsen, N.E. Drenck, J.J. Christensen and H.K. Johansen. 2011. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J. Clin. Microbiol. 49: 3300–3308.
• Bassetti M., F. Ansaldi, L. Nicolini, E. Malfatto, M.P. Molinari, M. Mussap, B. Rebesco, F. Bobbio Pallavicini, G. Icardi and C. Viscoli. 2009. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64: 625–629.
• Batura-Gabryel H. Deep mycoses in Poland – candidosis [in:] Medical Mycology Medical Doctor and Students. (in Polish) Editor: Adamski Z., Batura-Gabryel H., Wydawnictwo Naukowe Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. Poznan, Poland, 2007: 90–96.
• Borg von Zepelin M., L. Kunz, R. Rüchel, U. Reichard, M. Weig and U. Gross. 2007. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungemia in Germany from July 2004 to August 2005, J. Antimicrob. Chemother. 60: 424–428.
• Chen S.C., D. Marriott, E.G. Playford, Q. Nguyen, D. Ellis, W. Meyer, T.C. Sorrell, M. Slavin, Australian Candidaemia Study. 2009. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin. Microbiol. Infect. 15: 662–669.
• Cisterna R., G. Ezpeleta, O. Telleria, Spanish Candidemia Surveillance Group. 2010. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J. Clin. Microbiol. 48: 4200–4206.
• Costa de Oliveira S., I. Marcos Miranda, R.M. Silva, E. Pinto, A. Silva, R. Rocha, A. Amorim, A. Gonçalves Rodrigues and C. Pina-Vaz. 2011. FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy, Antimicrob. Agents. Chemother. 55(3): 1312–1314.
• Cuenca-Estrella M., L. Rodero, G. García-Effrón and J.L. Rodriguez-Tudela. 2002. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999, J. Antimicrob. Chemother. 49: 981–987.
• Fadda M.E., G.S. Podda, M.B. Pisano, M. Deplano and S. Cosentino. 2008. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey, J. Prev. Med. Hyg. 49(2): 69–74.
• Falagas M.E., N. Roussos and K.Z. Vardakas. 2010. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis. 14: e954–e966.
• Fleck R., A. Dietz and H. Hof. 2007. In vitro susceptibility of Candida species to five antifungal agent in a German university hospital assessed by the reference broth microdilution method and Etest, J. Antimicrob. Chemother. 59: 767–771.
• González M.G., M. Elizondo and J. Atala. 2008. Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance Study, J. Clin. Microbiol. 46: 2902–2905.
• Gumbo T., C.M. Isada, G. Hall, M.T. Karafa and S.M. Gordon. 1999. Candida glabrata fungemia. Clinical features of 139 patients. Medicine 78: 220–227.
• Hitchcock C.A., G.W. Pye, P.F. Troke, E.M. Johnson and D.W Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37: 1962–1965.
• Horasan E.S., G. Ersöz, M. Göksu, F. Otag, A.O. Kurt, S. Karaçorlu and A. Kaya. 2010. Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia 170: 263–268.
• Kalkanci A., E. Berk, B. Aykan, K. Caglar, K. Hizel, D. Arman and S. Kustimur. 2007. Epidemiology and antifungal susceptibility of Candida species isolated from hospitalized patients. J. Mycol. Méd. 17: 16–20.
• Kubisiak-Rzepczyk H., E. Szponar and Z. Adamski. 2008. The evaluation of the qualitative and susceptibility testing of Candida species isolated from the oral cavity plate denture users (in Polish). Dental Forum 1: XXXVI.
• Kucharíková S., P. Van Dijc, M. Lisalová and H. Bujdáková. 2010. Effect of antifungals on itraconazole resistant C. glabrata. Cent Europ. J. Biology 5: 318–323.
• Laupland K.B., B.D. Gregson, D.L. Church, T. Ross and S. Elsayed. 2005. Invasive Candida species infections: a 5 year population-based assessment, J. Antimicrob. Chemother. 56: 532–537.
• Lockhart S.R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger and D.R. Soll. 1999. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J. Dent. Res. 78: 857–868.
• Macura A.B. and M. Skóra. 2009. Antifungal susceptibility testing of fungi isolated from vagina. (in Polish). Mikol. Lek. 16: 206–209.
• Martin D., F. Persat, M.A. Piens and S. Picot. 2005. Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001. Eur. J. Clin. Microbiol. Infect. Dis. 24: 329–333.
• McMullan R., R. McClurg, J. Xu, J.E. Moore, B.C. Millar, M. Crowe and S. Hedderwick. 2002. Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000. J. Infect. 45: 25–28.
• Messer S.A., G.J. Moet, J.T. Kirvy and R.N. Jones. 2009. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J. Clin. Microbiol. 47: 1942–1946.
• Negri M., S. Silva, M. Henriques and R. Oliveira. 2012. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur. J. Clin. Microbiol. Infect. Dis. 31: 1399–412.
• Nguyen M.H., J.E. Peacock, A.J. Morns, D.C. Tanner, M.L. Nguyen, D.R. Snydman, M.M. Wagener, M.G. Rinaldi and V.L. Yu.1996. The changing face of Candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100: 617–623.
• Nishikaku A.S., Melo A.S.A. and Colombo A.L. 2010. Geographic trends in invasive Candidiasis. Curr Fungal Infect Rep. 4: 210–8.
• Nucci M., Marr A.K. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41: 521–526.
• Passos X.S., Costa C.R., Araújo C.R., Nascimento E.S., Souza L.K., Fernandes Ode F., Sales W.S. and Silva Mdo. R. 2007. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital, Mycopathologia 163: 145–151.
• Pfaller M.A., L. Boyken, R. Hollis, J. Kroeger, S.A. Messer, S. Tendolkar and D.J. Diekema. 2008. In vitro Susceptibility of Invasive Isolates of Candida spp. To Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150–156.
• Pfaller M.A., M. Castanheira, S.A. Messer, G.J. Moet and R.N. Jones. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69: 45–50.
• Pfaller M.A., D.J. Diekema, M. Rinaldi, R. Barnes, B. Hu, A.V. Veselov, N. Tiraboschi, E. Nagy and D.L. Gibbs. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing: J. Clin. Microbiol. 43: 5848–5859.
• Rex J.H., M.G. Rinaldi and M.A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1–8.
• Ruan S.Y., Y.T. Huang, C.C. Chu, C.J. Yu and P.R. Hsueh. 2009. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes. Int. J. Antimicrob. Agents. 34(3): 236–239.
• Safdar A., F. van Rhee, J.P. Henslee-Downey, S. Singal and J. Mehta. 2001. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 28: 873–878.
• Saracli M.A., R. Gumral, H.C. Gul, A. Gonlum and S.T. Yildiran. 2009. Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish Tertiary Care Military Hospital, recovered through 2001 and 2006, Milit. Med. 174: 860–865.
• Sipsas N.V., R.E. Lewis, I.I. Raad and D.P Kontoyiannis. 2009. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. Internat. J. Antimicrob. Agents. 34: 95–98.
• Sobel J.D. 2000. Management of infections caused by Candida glabrata. Curr. Infect. Dis. Rep. 2: 424–428.
• Swinne D., N. Nolard, P. Van Rooij and M. Detandt. 2009. Short report Bloodstream yeast infections: a 15 – month survey. Epidemiol Infect Cambridge University Press. 137: 1037–1040.
• Szymankiewicz M. 2007. In vitro susceptibility of C. parapsilosis strains isolated from diffrent clinical materials to fluconazole (in Polish). Mikol. Lek. 14: 37–40.
• Szymankiewicz M. and M. Dancewicz. 2008. Evaluation of voriconazole and caspofungin in vitro activity against Candida spp. strains using E-test method. (in Polish) Mikol. Lek. 15: 13–15.
• Tortorano A.M., C. Kibbler, J. Peman, H. Bernhardt, L. Klingspor and R. Grillot. 2006. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents. 27: 359–66.
• Tortorano A.M., J. Peman, H. Bernhardt, L. Klingspor, C.C. Kibbler, O. Faure, E. Biraghi, E. Canton, K. Zimmermann, S. Seaton and others. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23: 317–22.
• Trick W.E., S.K. Fridkin, J.R. Edwards, R.A. Hajjeh and R.P. Gaynes. 2002. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis. 35: 627–630.
• Uzun O., S. Ascioglu, E.J. Anaissie and J.H. Rex. 2001. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Antimicrob. Agents Chemother. 32: 1713–1717.
• Vazquez J.A., G. Peng, J.D. Sobel, L. Steele-Moore, P. Schuman, W. Holloway and J.D. Neaton. 2001. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin. Infect. Dis. 33: 1069–1075.
• Wieczorek P., P. Sacha, M. Żórawski, P. Jakoniuk and E. Tryniszewska. 2008. In vitro activity of caspofungin against strains of Candida (in Polish). Mikol. Lek. 15: 135–139.
• Wisplinghoff H., T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel,M.B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 1; 39(3): 309–17.